Roche’s Cancer Drug Moves Forward
Roche Holdings Ltd. (RHHBY) reported positive top-line data on trastuzumab emtansine (T-DM1) from a late-stage trial (EMILIA) conducted in patients suffering from HER2-positive metastatic breast cancer, who had been treated with Herceptin (trastuzumab) and taxane chemotherapy. The phase III trial compared patients treated with trastuzumab emtansine to those treated with GlaxoSmithKline’s (NYSE:GSK) lapatinib plus Xeloda [...]
Roche Holdings Ltd. (RHHBY) reported positive top-line data on trastuzumab emtansine (T-DM1) from a late-stage trial (EMILIA) conducted in patients suffering from HER2-positive metastatic breast cancer, who had been treated with Herceptin (trastuzumab) and taxane chemotherapy. The phase III trial compared patients treated with trastuzumab emtansine to those treated with GlaxoSmithKline’s (NYSE:GSK) lapatinib plus Xeloda (capecitabine).
The trial results demonstrated that patients dosed with … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards